VIVUS Inc

VIVUS — Obesity Week Preconference Session 2013

26 slides from VIVUS's conference presentation, Nov 12, 2013

  1. Slide 1: Obesity Week Preconference Session

    OBESITY WEEK Preconference Session ©2013 VIVUS Inc. All rights reserved | www.vivus.com November 12, 2013 Barbara Troupin, MD, MBA VP, Scientific Communication & Risk Management

  2. Slide 2: Forward Looking Statement

    FORWARD LOOKING STATEMENT ©2013 VIVUS Inc. All rights reserved | www.vivus.com 1 Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "ant

  3. Slide 3: Qsymia Prescribing Information

    QSYMIA PRESCRIBING INFORMATION About Qsymia Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (ove

  4. Slide 4: EQUIP: Significant Weight Loss Occurred Early and Was Sustained

    EQUIP: SIGNIFICANT WEIGHT LOSS OCCURRED EARLY AND WAS SUSTAINED (SEVERELY OBESE PATIENTS) P<.0001 for both doses vs placebo, and 15 mg/92 mg vs 3.75 mg/23 mg at all time points for both completers and ITT-LOCF. LS=least-squares. EWL=excess weight loss, Excess weight is defined as the weight in exces

  5. Slide 5: CONQUER: Significant Weight Loss Was Sustained

    ITT-LOCF CONQUER: SIGNIFICANT WEIGHT LOSS WAS SUSTAINED (PATIENTS WITH MULTIPLE COMORBIDITIES) P<.0001 for both doses vs placebo, and 15 mg/92 mg vs 7.5 mg/46 mg at all time points for both completers and ITT-LOCF. 1. Qsymia [prescribing information]. Mountain View, CA: VIVUS, Inc.; 2013. 2. Data on

  6. Slide 6: Qsymia: Improvement in Risk Factors

    QSYMIA: IMPROVEMENT IN RISK FACTORS Diastolic BP Systolic BP Fibrinogen Triglycerides TChol:HDL IWQOL total Fasting glucose HOMA-IR Fasting insulin HbA1c hs-CRP ALT Apnea Hypopnea Index Placebo subtracted effect size Placebo subtracted effect size Favors Qsymia Favors Placebo Favors Qsymia Favors Pl

  7. Slide 7: SEQUEL: Weight Loss Sustained Over Two Years

    SEQUEL: WEIGHT LOSS SUSTAINED OVER TWO YEARS *p<0.0001 vs placebo. Garvey WT et al. Am J Clin Nutr. 2012 ITT-LOCF Completers & ITT-LOCF -10.8% -38.4% -41.5% Completers EWL 108 108 -1.8% -9.3%* -10.5%* -9.3%* -10.7%* -2.2% 6 - 16 - 14 - 12 - 10 - 8 - 6 - 4 - 2 0 Percent Weight Loss (LS Mean) Week Pla

  8. Slide 8: Commonly Reported Adverse Events and AEs Leading to Discontinuation

    Please consult complete adverse event tables available in the full Prescribing Information for Qsymia. Qsymia [prescribing information]. Mountain View, CA: VIVUS, Inc.; 2013. Most Common Adverse Events, % Paraesthesia 1.9 4.2 13.7 19.9 Dry mouth 2.8 6.7 13.5 19.1 Constipation 6.1 7.9 15.1 16.1 Dysge

  9. Slide 9: Obesity Market Evolution

    OBESITY MARKET EVOLUTION 8

  10. Slide 10: New AACE Treatment Algorithm: Medical Therapy Now Recommended

    NEW AACE TREATMENT ALGORITHM (MAY-2013): MEDICAL THERAPY IS NOW RECOMMENDED 9 Obesity management and FDA-approved anti-obesity medications now recommended for: Prediabetes Diabetes Dyslipidemia Hypertension 1st ever inclusion of drug therapy in treatment algorithm Primary Care Physicians refer to AA

  11. Slide 11: Greater Recognition of Obesity as a Disease

    GREATER RECOGNITION OF OBESITY AS A DISEASE Jun-2013 - For the first time, obesity is recognized as a disease by the leading medical association in the U.S. AMA recognition is important support for policy makers, healthcare providers and payers 10

  12. Slide 12: Treat and Reduce Obesity Act of 2013

    TREAT AND REDUCE OBESITY ACT OF 2013 Introduced into House and Senate Jun-2013 Among other provisions, the Act would remove the Medicare Part D exclusion of obesity medications Bi-partisan support Senators Carper (D-DE), Murkowski (R-AK) Representatives Cassidy (R-LA), Kind (D-WI) 11

  13. Slide 13: Qsymia Recent Highlights

    QSYMIA RECENT HIGHLIGHTS 12

  14. Slide 14: Qsymia Educationally-Focused REMS

    QSYMIA EDUCATIONALLY-FOCUSED REMS Goal: to inform prescribers and female patients of reproductive potential regarding: the increased risk of congenital malformations, specifically orofacial clefts, in infants exposed to Qsymia during the first trimester of pregnancy, the importance of pregnancy prev

  15. Slide 15: Qsymia Retail Roll-out Success

    QSYMIA RETAIL ROLL-OUT SUCCESS Certified Retail Pharmacy Status (31-Oct-2013) >31,000 pharmacies now certified to dispense Qsymia Chains include: A&P, Albertsons, Costco, CVS, Kmart, Kroger, Publix, Rite Aid, Safeway, Walgreens/Duane Reade, Walmart, Wegmans, Winn-Dixie, many others Prescriber and pa

  16. Slide 16: Qsymia Retail Pharmacy Availability Created a Step-Up in Demand in 3Q2013

    # Prescribers # TRxs Launch thru Sep-2013 ~29,000 ~280,000 Added in 3Q2013 ~8,000 ~109,000 Source: Vivus Data on file- 10/4/2013 file. * Estimates pending finalization and reversals % Growth 97% 37% 35% QSYMIA RETAIL PHARMACY AVAILABILITY CREATED A STEP-UP IN DEMAND IN 3Q2013 15

  17. Slide 17: Qsymia Reimbursement Continues to Improve

    QSYMIA REIMBURSEMENT CONTINUES TO IMPROVE As of 30-Sep-2013, ~38% of U.S. Commercial Lives have access to Qsymia at Tier 3 or better, up from <20% at approval 16 Qsymia Access: % of U.S. Commercial Lives

  18. Slide 18: Recent Publication Reports Impact of Qsymia on Type 2 Diabetes

    RECENT PUBLICATION REPORTS IMPACT OF QSYMIA ON TYPE 2 DIABETES “Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended-Release” W. Timothy Garvey, MD, et al. Diabetes Care (epub Oct 8, 2013) Patients on the Recommended (7.5/

  19. Slide 19: SEQUEL: Incidence Rates of Type 2 Diabetes Reduced Over 108 Weeks

    SEQUEL: INCIDENCE RATES OF TYPE 2 DIABETES REDUCED WITH QSYMIA OVER 108 WEEKS 18 The annualized incidence rate of type 2 diabetes was reduced with Qsymia by 70.5-78.7 % compared to placebo/lifestyle Prediabetes and/or Metabolic Syndrome Population Garvey WT, et al. Diabetes Care. 2013. [epub ahead o

  20. Slide 20: Qsymia Experience on Market

    QSYMIA EXPERIENCE ON MARKET 19

  21. Slide 21: Drug Utilization Study OB-303 (CONQUER)

    DRUG UTILIZATION STUDY OB-303 (CONQUER) Age (years) 51 BMI, kg/m2 37 Female, % 70 Hypertension Hx, % 53 Dyslipidemia Hx, % 36 Diabetes Hx, % 16 Hx=history 20

  22. Slide 22: Drug Utilization Study OB-303 (CONQUER)

    DRUG UTILIZATION STUDY OB-303 (CONQUER) Drug Utilization Study Age (years) 51 49 BMI, kg/m2 37 37 Female, % 70 78 Hypertension Hx, % 53 42 Dyslipidemia Hx, % 36 50 Diabetes Hx, % 16 19 Hx=history. Data from first 10 months on market, reported in July 2013 70% of patients are aged 18-54 years old Sou

  23. Slide 23: Qsymia Prescribers & Prescriptions by Specialty

    Source: Vivus Data on file – launch-to-date (through 30-Sep-2013) QSYMIA PRESCRIBERS & PRESCRIPTIONS BY SPECIALTY 22

  24. Slide 24: Qsymia Post-Marketing Experience

    Most Commonly Reported Spontaneous AEs (consistent w/US Package Insert and clinical trials data) Paraesthesia Headache Dizziness Dry Mouth Insomnia ~90% of patients are on the recommended dose (7.5/46) QSYMIA POST-MARKETING EXPERIENCE 23 Source: Vivus Data on file – 10-25-2013

  25. Slide 25: Qsymia Summary

    QSYMIA SUMMARY Qsymia was approved by FDA in Jul-2012; launched Sep-2012 First and only medication that provides sustained, best-in-class weight loss efficacy in excess of 10% Clinically relevant improvements in multiple cardiometabolic and other risk factors Well tolerated; known risks are appropri

  26. Slide 26: Summary

    SUMMARY Obesity treatment landscape evolving Treatment being used in appropriate patient population Access and coverage slowly but steadily improving This market is starting to build, and will only benefit from additional new entrants and investment 25

Vivus — Obesity Week Preconference Session 2013 on 6ix